Correlation Between Novo Nordisk and NervGen Pharma

Can any of the company-specific risk be diversified away by investing in both Novo Nordisk and NervGen Pharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Novo Nordisk and NervGen Pharma into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Novo Nordisk AS and NervGen Pharma Corp, you can compare the effects of market volatilities on Novo Nordisk and NervGen Pharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Novo Nordisk with a short position of NervGen Pharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Novo Nordisk and NervGen Pharma.

Diversification Opportunities for Novo Nordisk and NervGen Pharma

0.42

Correlation Coefficient

Novo Nordisk  NervGen Pharma

Very weak diversification

The 3 months correlation between Novo and NervGen is 0.42. Overlapping area represents the amount of risk that can be diversified away by holding Novo Nordisk AS and NervGen Pharma Corp in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on NervGen Pharma Corp and Novo Nordisk is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Novo Nordisk AS are associated (or correlated) with NervGen Pharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of NervGen Pharma Corp has no effect on the direction of Novo Nordisk i.e., Novo Nordisk and NervGen Pharma go up and down completely randomly.

Pair Corralation between Novo Nordisk and NervGen Pharma

Considering the 90-day investment horizon Novo Nordisk AS is expected to under-perform the NervGen Pharma. In addition to that, Novo Nordisk is 1.49 times more volatile than NervGen Pharma Corp. It trades about -0.11 of its total potential returns per unit of risk. NervGen Pharma Corp is currently generating about -0.13 per unit of volatility. If you would invest  216.00  in NervGen Pharma Corp on December 29, 2024 and sell it today you would lose (32.00) from holding NervGen Pharma Corp or give up 14.81% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Novo Nordisk AS  vs.  NervGen Pharma Corp

Novo Nordisk AS

Risk-Adjusted Performance

Very Weak

Over the last 90 days Novo Nordisk AS has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in April 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

NervGen Pharma Corp

Risk-Adjusted Performance

Very Weak

Over the last 90 days NervGen Pharma Corp has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fragile performance in the last few months, the Stock's basic indicators remain nearly stable which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long-run up-swing for the company stockholders.

Pair Trading with Novo Nordisk and NervGen Pharma

The main advantage of trading using opposite Novo Nordisk and NervGen Pharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Novo Nordisk position performs unexpectedly, NervGen Pharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in NervGen Pharma will offset losses from the drop in NervGen Pharma's long position.

The idea behind Novo Nordisk AS and NervGen Pharma Corp pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.